Clinical Trial Search

Primary: Number of Participants With Adverse Events Including Laboratory Abnormalities at the End of Study Participation — 4; 5 participants

Primary: Number of Participants With Each Category of Adverse Events in Stage I — 5; 4; 5; 5 Participants

Primary: Number of Participants With Treatment-Emergent Adverse Events — 9; 8; 10; 11 Participants

Primary: Percentage Change From Baseline in VAS (Visual Analog Scale) With Air Stimulation — -51.44; -51.59; -41.59; -38.64 percentage change from baseline

Primary: Change From Baseline in Target Engagement Biomarkers- Soluble Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) Complexed to GSK3196165 — 0.972; 13.799; 0.960…

Primary: Percentage of Participants With 3-year Progression-free Survival (PFS) — 90 percentage of participants

Primary: Objective Response Rate (ORR) by Investigator Assessment — 12.3 percentage of participants

Primary: Total Number of Gd-Enhancing T1-Weighted MRI Lesions Per Scan Averaged During Weeks 12, 16, 20, and 24 — 1.819; 0.710; 1.237; 1.477 lesions per scan

Primary: Daily "Average Pain Over the Last 24 Hours" Score at Week 4 — 5.9; 5.9; 6.1; 5.9 score on a scale

Primary: Event Free Survival (EFS) at 1 Year — 26; 65 percentage of participants

Primary: Percentage of Participants With Plasma HIV-1 Ribonucleic Acid (RNA) < 50 Copies Per Milliliter (c/mL) at Week 24 — 80; 69; 76; 72 Percentage of Participants

Primary: Change From Baseline in Schiff Sensitivity Score — 2.59; 2.68; 2.52; -1.94 Score on Scale — p=<0.0001

Primary: Change From Baseline in Neuropsychological Test Battery in Total Z-score After 12-week Treatment. — 0.13; 0.17; 0.16; 0.01 Z-score — p=0.7907

Primary: Radiographic Response Rates — 19 Participants

Primary: Participant Pain Assessment — -3.9; -2.2; -3.6; -4.3 units on a scale — p=0.33